The enzyme induction potential of a drug candidate and its metabolites is typically evaluated first in vitro by measuring mRNA expression. Nuvisan has implemented a bDNA-based multiplexing technology for mRNA quantification. On top of providing economic benefits compared to conventional qPCR, this methodology also offers the opportunity to gain a deeper understanding of the mechanism of action of the drug candidate. Moreover, various options for customizing the CYP induction experiments driven by the drug’s characteristics can generate added value.
